Showing 1 posts of 1 posts found.
Novartis (SIX: NOVN) has announced the results from a Phase III clinical trial which shows that Afinitor (everolimus) significantly reduced …
From lab breakthrough to NHS treatment: Getting innovative therapies to patients
Five Facts about NHS and primary care
Clinical trials don’t just have a recruitment problem, they have an enrolment protection problem.
AI in pharma: From lab development to patient impact
Back to basics: X-ray inspection in pharmaceutical and medical device production